Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Death in Lebanon

 
The Ministry of Public Health launched in collaboration with the national committee for the prevention of cardiovascular diseases and Yaduna -Women Heart Health Center the National campaign for the early detection and prevention of cardiovascular diseases under the title “Don’t wait, your heart can’t wait”, during a conference held under the patronage and in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani at the Adnan Kassar Edifice in Bir Hassan.
 
The Head of Primary health care Department at Health Ministry Dr. Randa Hamadeh made a presentation of the path of the national campaign. “This campaign that starts today will last for three months until the end of April. It will kick off from the national network of primary health care centers located across all the Lebanese territory and aims at providing services to citizens, i.e. free cardiovascular examinations for men and women,”Dr. Hamadeh added.
 
The Chairperson of Yaduna foundation Wafaa Sleiman delivered a statement in which she noted that the increasing number of women who underwent an early testing at the Women Heart Health Center, and the detection of many cases of cardiovascular diseases contributed greatly in the treatment of these cases, and led us to activate the prevention and awareness actions across all the Lebanese territory.
 
Hasbani

In a statement, Hasbani noted that the non-communicable diseases cause the death of 38 million people each year, 28 million death cases of which occur in low- and middle-income countries.

“Non-communicable diseases threaten the progress towards achieving the Millennium Development Goals. Poverty and such diseases are highly correlated and it is expected that the rapid growth of these diseases hinder poverty alleviation initiatives in low-income countries, in particular by increasing household costs associated with healthcare services,” Hasbani added.
 
Hasbani highlighted that this activity complements all these efforts, especially that it is integrated with that of Yaduna - Women Heart Health Center, knowing that the primary healthcare brings together all sectors to provide best services to citizens.(Read more...)
    1
ATC Name B/G Ingredients Dosage Form Price
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution 135,545,977 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution 216,872,714 L.L
J05AR10 KALUVIA G Lopinavir - 200mg, Ritonavir - 50mg Tablet, film coated 7,632,790 L.L
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01XA02 KARBOTEEN G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 2,080,268 L.L
L01XA02 KARBOTEEN G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 250mg/5ml 250mg/5ml Granules for suspension 477,384 L.L
J01DB01 KEFLEX B Cefalexin (monohydrate) - 500mg 500mg Capsule 659,123 L.L
N03AX14 KEPAM MS G Levetiracetam - 500mg/5ml 500mg/5ml Injectable solution 9,170,015 L.L
N03AX14 KEPCITAM G Levetiracetam - 500mg 500mg Tablet, film coated 2,933,608 L.L
N03AX14 KEPCITAM G Levetiracetam - 1000mg 1000mg Tablet, film coated 3,119,058 L.L
N03AX14 KEPPRA B Levetiracetam - 250mg 250mg Tablet, film coated 3,240,855 L.L
N03AX14 KEPPRA B Levetiracetam - 500mg 500mg Tablet, film coated 6,245,576 L.L
N03AX14 KEPPRA B Levetiracetam - 1000mg 1,000mg Tablet, film coated 11,749,079 L.L
C03DA05 KERENDIA G Finerenone - 10mg 10mg Tablet, film coated 6,353,687 L.L
C03DA05 KERENDIA G Finerenone - 20mg 20mg Tablet, film coated 6,353,687 L.L
C07AB05 KERLONE B Betaxolol HCl - 20mg 20mg Tablet, film coated, scored 575,165 L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution 94,290,414 L.L
N01AX03 KETAMINE PANPHARMA G Ketamine HCl - 250mg/5ml 250mg/5ml Injectable solution 1,534,668 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 25mg 25mg Tablet, film coated 399,121 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 50mg/2ml 50mg/2ml Injectable concentrated solution 435,405 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 50mg/2ml 50mg/2ml Injectable solution 435,405 L.L
M01AB15 KETO-AVI G Ketorolac tromethamine - 30mg/ml 30mg/ml Injectable solution 106,164 L.L
D01AC08 KETOCONAZOLE KORHISPANA G Ketoconazole - 2% 2% Gel 599,354 L.L
M01AB15 KETOLAC G Ketorolac trometamine - 10mg 10mg Tablet 268,769 L.L
M01AB15 KETOLAC G Ketorolac trometamine - 30mg/2ml 30mg/2ml Injectable solution 268,769 L.L
M01AE03 KETOPROFENE MACOPHARMA G Ketoprofen - 100mg/100ml 100mg/100ml Injectable solution 329,241 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026